Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured approximately $400 million in orders in 2024 and 2025 associated with its...

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weaponSupports the government’s continued efforts and long-term strategy to maintain...